In silico methods for de-immunization of small drugs, therapeutic proteins and monoclonal antibodies - ImmunoBench
| Reference number | |
| Coordinator | SciCross AB |
| Funding from Vinnova | SEK 420 000 |
| Project duration | March 2014 - July 2014 |
| Status | Completed |
Important results from the project
The aim of the project was to evaluate the R&D efforts needed in order commercialise SciCross planned services/products within the field of immunogenicity assessment. The results of this study fulfils these objective and will be used for a full Utvecklingsprojekt application. Several areas was identified where focused R&D activities will give SciCross an advantage towards our competitors.
Expected long term effects
The result of this study show that there is a great potential for SciCross services/products. This has been verified by discussions with key opinion leaders in the field, analysis of drug development pipelines and evaluation of current methods. A number of gaps in existing offers have been identified and strategies to reach the market in these cases have been evaluated.
Approach and implementation
The project was performed in three different workpackages: WP1: Prototype of software; WP2: Need for R&D, proof of concept, analysis of existing data, discussion with potential customers; WP3: Market analysis. The summarised results from all WPs shows that there are good opportunities to successfully reach the market after a focused R&D effort.